Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.88 USD | -3.06% | -6.33% | +174.92% |
05-28 | Johnson & Johnson Acquires Experimental Eczema Drug for $1.25 Billion | MT |
05-15 | Needham Adjusts Price Target on Arcutis Biotherapeutics to $18 From $16, Maintains Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+174.92% | 1.03B | |
+9.83% | 115B | |
+10.80% | 105B | |
-10.84% | 22.71B | |
-1.46% | 21.83B | |
-11.04% | 18.18B | |
-41.92% | 16.52B | |
-15.11% | 16.01B | |
+6.62% | 14.14B | |
+17.53% | 10.71B |
- Stock Market
- Equities
- ARQT Stock
- News Arcutis Biotherapeutics, Inc.
- Goldman Sachs Adjusts Price Target on Arcutis Biotherapeutics to $33 From $44, Maintains Buy Rating